A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

Summary

The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severely active ulcerative colitis.

Timeline

Start

2023-10-09

Primary completion

2024-09-26

Completion

2026-01-05

Outcome

Met primary endpoint

release “In the ANTHEM-UC study (n=252), three doses of once daily icotrokinra were tested with all meeting the primary endpoint of clinical response at Week 12.” jnj.com ↗

Drugs

Indications